necuparanib + nab-paclitaxel + gemcitabine

This drug combination consists of **necuparanib**, a rationally engineered low molecular weight heparin derivative (also known as M402), **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel), and **gemcitabine**, a nucleoside analog used as chemotherapy. Necuparanib is designed to reduce anticoagulant properties while retaining anti-tumor effects, acting as a heparan sulfate mimetic that can disrupt tumor microenvironment factors involved in proliferation, metastasis, and invasion[1][2][4][5]. Nab-paclitaxel stabilizes microtubules inhibiting mitosis, while gemcitabine is incorporated into DNA and causes cell death by disrupting DNA synthesis. This combination has been evaluated for first-line treatment of metastatic pancreatic ductal adenocarcinoma, aiming to improve response rates and survival.

Other names

necuparanibnab-paclitaxelgemcitabine